Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

By A. Cheng, Yoon-Koo Kang, Zhendong Chen, C. Tsao, S. Qin, Jun Suk Kim, R. Luo, Jifeng Feng, S. Ye, Tsai‐Sheng Yang and 11 more. The Lancet Oncology, 2009

5,311 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/4e5f41733aa7db34f0a1bd2e051055743163ffe8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Jordi Bruix1 , 2
2. J. Llovet
3. M. Sherman
4. L. Kulik
5. Amit G. Singal
6. R. Finn
7. V. Mazzaferro
8. Andrew X. Zhu

In Hepatology

1. J. Llovet
2. Jordi Bruix1 , 2
3. M. Sherman
4. Riccardo Lencioni
5. V. Mazzaferro
6. Amit G. Singal
7. L. Kulik
8. Alejandro Forner1 , 2

Citations in the corpus

• Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. (2010, background): “Age (y) Younger than 65 138 (47) 65 or older 153 (53) 75 or older 64 (22) Sex Male 223 (77) Female 68 (23) Ethnicity White 208 (71) Black 37 (13) Asian 29 (10) Hispanic 17 (6) Etiology Hepatitis C virus 100 (34) Alcohol 56 (19) Cryptogenic 54 (19) Hepatitis B virus 26 (9) Hepatitis C virus and alcoh”
• Metallothionein-1G Facilitates Sorafenib Resistance through Inhibition of Ferroptosis (2016, background): “In two randomized phase III clinical trials of advanced HCC patients,((4,5)) sorafenib treatment improved the time to progression and extended overall survival by 2.”
• Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2019, background): “The magnitude of benefit was confirmed in a similarly designed phase 3 study performed in the Asia-Pacific region exclusively.(163) Since this time, phase 3 studies of novel combinations or single agents have not been able to demonstrate a survival advantage over sorafenib.”
• Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma (2010, methodology): “24 HCV 56 (46) 42 (35) HCV alcohol 2 (2) 6 (4) HBV 12 (10) 13 (11) NASH 1 (1) 5 (4) Cryptogenic 25 (20) 28 (23) Unknown 5 (4) 9 (7) Method of diagnosis Imaging 71 (58) 68 (55) .”